Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine

http://www.ncbi.nlm.nih.gov/pubmed/25515765

http://www.readcube.com/articles/10.1111%2Fced.12488

Clin Exp Dermatol. 2014 Dec 16. doi: 10.1111/ced.12488. [Epub ahead of print]

Lock AD, McNamara CJ, Rustin MH.

Abstract

Systemic mastocytosis (SM) is a myeloproliferative disorder, characterized by a clonal proliferation of abnormal mast cells accumulating in internal organs and sometimes in the skin, leading to cutaneous and systemic symptoms. Mutations within the gene KIT, which encodes the receptor tyrosine kinase (KIT) on mast cells, is found in most patients with SM. We report a case of a 62-year-old woman presenting with a pruritic rash on her limbs and trunk. Several years later she developed gastrointestinal symptoms, associated with raised serum tryptase. Skin and bone marrow biopsies confirmed a diagnosis of SM, initially presenting with urticaria pigmentosa. Responses to multiple therapies, including potent topical steroids, oral antihistamines, phototherapy and the tyrosine kinase inhibitor, nilotinib, were inadequate. Treatment with cladribine (2-chlorodeoxyadenosine) produced a marked and sustained reduction in her symptoms and serum tryptase level.

© 2014 British Association of Dermatologists.

About mastopedia

Mastopedia moderates information on Mastocytosis, Urticaria Pigmentosa, Mast Cell Activation Disorder / Syndrome, Idiopathic Anaphylaxis and related disorders. www.mastopedia.com
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a comment